Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Enhanced susceptibility to chemical induction of ovarian tumors in mice with a germ line p53 mutation.

Wang Y, Zhang Z, Lu Y, Yao R, Jia D, Wen W, LaRegina M, Crist K, Lubet R, You M.

Mol Cancer Res. 2008 Jan;6(1):99-109. doi: 10.1158/1541-7786.MCR-07-0216.

2.

p53 Transgenic mice are highly susceptible to 4-nitroquinoline-1-oxide-induced oral cancer.

Zhang Z, Wang Y, Yao R, Li J, Lubet RA, You M.

Mol Cancer Res. 2006 Jun;4(6):401-10. Erratum in: Mol Cancer Res. 2006 Aug;4(8):599. Li, Jie [added].

3.

Gene expression in the lung of p53 mutant mice exposed to cigarette smoke.

Izzotti A, Cartiglia C, Longobardi M, Bagnasco M, Merello A, You M, Lubet RA, De Flora S.

Cancer Res. 2004 Dec 1;64(23):8566-72.

4.

Induction of invasive mouse skin carcinomas in transgenic mice with mutations in both H-ras and p53.

Zhang Z, Yao R, Li J, Wang Y, Boone CW, Lubet RA, You M.

Mol Cancer Res. 2005 Oct;3(10):563-74.

6.

Molecular alterations and lung tumors in p53 mutant mice exposed to cigarette smoke.

De Flora S, Balansky RM, D'Agostini F, Izzotti A, Camoirano A, Bennicelli C, Zhang Z, Wang Y, Lubet RA, You M.

Cancer Res. 2003 Feb 15;63(4):793-800.

7.

Infrequent p53 mutations in 7,12-dimethylbenz[a]anthracene-induced mammary tumors in BALB/c and p53 hemizygous mice.

Jerry DJ, Butel JS, Donehower LA, Paulson EJ, Cochran C, Wiseman RW, Medina D.

Mol Carcinog. 1994 Mar;9(3):175-83.

PMID:
8142019
8.

[Immunohistochemical studies of recessive oncogene p53 and N-myc oncogene expression in 7, 12 dimethylbenz (a) anthracene-induced rat ovarian tumors].

Kataoka A, Nishida T, Sugiyama T, Hirakawa N, Maruuchi T, Imaishi K, Yakushiji M.

Nihon Sanka Fujinka Gakkai Zasshi. 1992 Apr;44(4):391-6. Japanese.

PMID:
1318915
9.
10.

Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development.

Wijnhoven SW, Zwart E, Speksnijder EN, Beems RB, Olive KP, Tuveson DA, Jonkers J, Schaap MM, van den Berg J, Jacks T, van Steeg H, de Vries A.

Cancer Res. 2005 Sep 15;65(18):8166-73.

11.

Use of p53 transgenic mice in the development of cancer models for multiple purposes.

Lubet RA, Zhang Z, Wiseman RW, You M.

Exp Lung Res. 2000 Dec;26(8):581-93. Review.

PMID:
11195457
12.

Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer.

Ku TK, Nguyen DC, Karaman M, Gill P, Hacia JG, Crowe DL.

Mol Cancer Res. 2007 Apr;5(4):351-62.

13.

Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.

Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, Hanash S, Misek DE, Katabuchi H, Williams BO, Fearon ER, Cho KR.

Cancer Cell. 2007 Apr;11(4):321-33.

14.
15.

p53 transgenic mice are highly susceptible to 1, 2-dimethylhydrazine-induced uterine sarcomas.

Zhang Z, Li J, Lantry LE, Wang Y, Wiseman RW, Lubet RA, You M.

Cancer Res. 2002 Jun 1;62(11):3024-9.

16.

In vivo expression and antitumor activity of p53 gene transfer with naked plasmid DNA in an ovarian cancer xenograft model in nude mice.

Collinet P, Vereecque R, Sabban F, Vinatier D, Leblanc E, Narducci F, Querleu D, Quesnel B.

J Obstet Gynaecol Res. 2006 Oct;32(5):449-53.

PMID:
16984510
17.
18.

Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors.

L'Espérance S, Popa I, Bachvarova M, Plante M, Patten N, Wu L, Têtu B, Bachvarov D.

Int J Oncol. 2006 Jul;29(1):5-24.

PMID:
16773180
19.

Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant.

Klein MA, Rüedi D, Nozaki M, Dell EW, Diserens AC, Seelentag W, Janzer RC, Aguzzi A, Hegi ME.

Oncogene. 2000 Nov 9;19(47):5329-37.

20.

Dimethylbenzanthracene carcinogenesis in Gadd45a-null mice is associated with decreased DNA repair and increased mutation frequency.

Hollander MC, Kovalsky O, Salvador JM, Kim KE, Patterson AD, Haines DC, Fornace AJ Jr.

Cancer Res. 2001 Mar 15;61(6):2487-91.

Supplemental Content

Support Center